![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.
Lead Product(s): BO-001
Therapeutic Area: Ophthalmology Product Name: BO-001
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: UI Investissement
Deal Size: $6.9 million Upfront Cash: Undisclosed
Deal Type: Financing June 03, 2024